#omalizumab

[mcatmemoranda2]

Xolair - omalizumab

Singulair - montelukast

[mathsbian]

On a related note to my last reblog:

The FDA approved a new drug last year in February (02/2024) to reduce allergic reaction intensity in people will allergies and food sensitivities (that cause anaphylaxis, sorry celiacs ☹️)!

It's not an emergency injection, it's a maintenance medication to give people with very severe allergies a bit more of a buffer to stop exposure (when it's accidental and noticed) or get treatment.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

The FDA approved a new medication for the reduction of allergic reactions that may occur with accidental exposure to one or more foods.

I saw an ad for the branded version, Xolair, yesterday on Tubi. I love seeing medical advancements!!

[cebozcom]

Antikörper-Therapien gegen allergische Erkrankungen | CeBoz.com

Eine Übersicht über Antikörper-Therapien zur Behandlung von allergischen Erkrankungen.

[theindianpharma]

Omalizumab is an FDA-approved drug used for the treatment of moderate-to-severe persistent asthma in adults and pediatric patients.

[ohthatswitty]

some of the drugs i'm learning sound like hebrew names

[michelvoss]

OMALIZUMAB (XOLAIR) BEI ALLERGISCHEM ASTHMA

arznei telegramm, 2006; 37: 3-4, 13.

Artikel ansehen

[medicalinklog]

Omalizumab es un anticuerpo monoclonal en contra de la IgE que se ha utilizado para el tratamiento de mantenimiento del asma bronquial alérgica, sin embargo se están realizando estudios para investigar nuevas indicaciones en enfermedades relacionadas con reacciones de hipersensibilidad tipo 1

Este ensayo clinico publicado en The New England Journal of Medicine (NEJM) evalúa la eficacia de omalizumab en pacientes con urticaria crónica

BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H1-antihistamines, even at high doses. In phase 2 trials, omalizumab, an IgE monoclonal antibody that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients.

METHODS In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite H1-antihistamine therapy (licensed doses). We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period. The primary efficacy outcome was the change from baseline in a weekly itch-severity score (ranging from 0 to 21, with higher scores indicating more severe itching).

RESULTS The baseline weekly itch-severity score was approximately 14 in all four study groups. At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was −5.1±5.6 in the placebo group, −5.9±6.5 in the 75-mg group (P=0.46), −8.1±6.4 in the 150-mg group (P=0.001), and −9.8±6.0 in the 300-mg group (P<0.001). Most prespecified secondary outcomes at week 12 showed similar dose-dependent effects. The frequency of adverse events was similar across groups. The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each).

CONCLUSIONS Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H1-antihistamines.